CN103405599A - Traditional Chinese medicine composition for treating rheumatic dermatosis - Google Patents
Traditional Chinese medicine composition for treating rheumatic dermatosis Download PDFInfo
- Publication number
- CN103405599A CN103405599A CN2013102608074A CN201310260807A CN103405599A CN 103405599 A CN103405599 A CN 103405599A CN 2013102608074 A CN2013102608074 A CN 2013102608074A CN 201310260807 A CN201310260807 A CN 201310260807A CN 103405599 A CN103405599 A CN 103405599A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- treatment
- kilograms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating dermatosis. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-13 parts of monkshood, 5-12 parts of kusnezoff monkshood root, 5-10 parts of nux vomica, 5-14 parts of asarum, 5-15 parts of arisaema heterophyllum, 5-25 parts of pinellia ternata, 5-17 parts of paris polyphylla, 5-18 parts of cynanchum paniculatum, 5-19 parts of angkut-angkut, 5-25 parts of scorpion, and 5-27 parts of centipede. The above raw materials can be made into the dosage forms including honeyed bolus, water-bindered pills, tablets, capsules, particle granules and oral liquid. The traditional Chinese medicine composition is applicable to dermatosis with various clinical types, has an effective rate of 95.2% and a cure rate of 79.8%.
Description
Technical field
The invention belongs to and take Chinese medicine and be the pharmaceutical composition of preparation of raw material, particularly dermopathic Chinese medicine composition.
Background technology
Dermatosis has many kinds, as lupus erythematosus, psoriasis, etc.Psoriasis, be commonly called as psoriasis, is apt to occur in person between twenty and fifty, and its course of disease delay repeatedly, is a kind of plain stubborn dermatosis.The psoriatic not only bears the misery of skin, also often suffers damage psychologically, and the person's of being in a bad way disability, even threat to life.
Modern medicine roughly is divided into three kinds of methods to psoriatic treatment: 1. topical skin treating; 2. ultraviolet illumination therapy; 3. systemic administration treatment, but all there is no to solve the basic problem of curing, no longer recurring.Chemicals commonly used such as aminopterin, ethyliminum, Ethylenediamine Tetraacetylimine, ciclosporin, methotrexate etc., the effect of the magic liquid of thick moral still belongs to obviously, but its toxic and side effects is strong, has limited their extensive use.Chinese medicine is according to the human body integral idea, and psoriasis is placed in to determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs under the background that the whole body internal organs change, and shown exclusive characteristics.The prescription medicine of the magic liquid of thick moral has report frequently, the curative effect of having nothing in common with each other, but at medication convenience, cure rate, prevent recurrence, generally the aspect such as applicable still can not make the people satisfied.Therefore, continuing to find more applicable, medicine better efficacy is the needs of the magic liquid of thick moral.
Summary of the inventionThe present invention treats the dermopathic Chinese medicine composition of rheumatism can also comprise Radix Notoginseng on the basis of above solvent, be applicable to deficiency of the kidney yin emission person particularly.Radix Notoginseng used weight proportioning is 5～30 weight portions, and the optimum weight proportioning is 20 parts.
The present invention aims to provide a kind of Chinese medicine composition for the treatment of the dermopathic Chinese medicine composition of rheumatism, it easily makes, easy to use, dermatosis is had to definite curative effect reliably.
The present invention is for the pharmaceutical composition of the enforcement treatment to the dermopathic Chinese medicine composition for the treatment of rheumatism, pharmacodynamic raw materials used and weight proportion thereof be, 5～13 parts of Radix Aconitis, 5～12 parts of Radix Aconiti Kusnezoffii, 5～10 parts of Semen Strychni, 5～14 parts of Herba Asaris, 5～15 parts of Rhizoma Arisaematiss, 5～25 parts of the Rhizoma Pinelliaes, 5～17 parts of Rhizoma Paridis, 5～18 parts of LIAODAOZHU, 5～19 parts of bee venom, 5～25 parts of Scorpios, 5～27 parts of Scolopendras.
The optimum weight proportioning of the medicine of the present invention treatment dermopathic Chinese medicine composition of rheumatism pharmacodynamic raw materials used is, 8 parts of Radix Aconitis, 6 parts of Radix Aconiti Kusnezoffii, 8 parts of Semen Strychni, 12 parts of Herba Asaris, 7 parts of Rhizoma Arisaematiss, 18 parts of the Rhizoma Pinelliaes, 11 parts of Rhizoma Paridis, 10 parts of LIAODAOZHU, 12 parts of bee venom, 13 parts of Scorpios, 14 parts of Scolopendras.
The magic liquid of the thick moral of the present invention can also comprise Radix Notoginseng on the basis of above solvent, be applicable to deficiency of the kidney yin emission person particularly.Radix Notoginseng used weight proportioning is 5～30 weight portions, and the optimum weight proportioning is 20 parts.
According to classic of TCM record and inventor observational study for many years, psoriatic formation is many because of Bad Eating Habit, and the product of the delicious food wind symptom that monophagia is pungent, positive higher are had a liking for tobacco and wine, cause yin asthenia generating intrinsic heat, noxious heat in the blood system is flourishing, the nutrient blood loss, living dry humorously, failure of skin and muscle to be nourished, cause primary disease.The body accumulation of heat can cause by many factors, and as internal injury caused by excess of seven emotions, the QI-mass harmony is stagnant, strongly fragrant fire-transformation of a specified duration, so that hyperactivity of heart-fire.The heat volt nutrient blood of heart governing blood and vessels, hyperactivity of heart-fire, then cause insufficiency of the spleen damp and hotly, outside adding, receiving heresy of six climate exopathogens and attack, interior foreign minister fights, and skin is impaired.
Pharmaceutical composition of the present invention can be made into the multi-medicament dosage form by usual way and orally use, and comprises the dosage forms such as honeyed pill, the watered pill, tablet, capsule, granular pattern electuary, oral liquid.Adult's oral dose every day is equivalent to crude drug 180～220 grams, and minutes 2～4 times oral.
The specific embodiment
By the following examples pharmaceutical composition of the present invention and formulation method are described in further detail.
Embodiment 1 prepares tablet
Get 10 kilograms of Radix Aconitis, 11 kilograms of Radix Aconiti Kusnezoffii, 8 kilograms of Semen Strychni, 9 kilograms of Herba Asaris, 11 kilograms of Rhizoma Arisaematiss, 12 kilograms of the Rhizoma Pinelliaes, 13 kilograms of Rhizoma Paridis, 12 kilograms of LIAODAOZHU, 8 kilograms of bee venom, 18 kilograms of Scorpios, 6 kilograms of Scolopendras, 10 kilograms, Radix Notoginseng, each medicine is merged and soaks into rear decoction 3 times, the each decoction 30～120 minutes, merging decoction liquor filters, be condensed into clear paste, granulation, drying, in flakes, sugar coating namely obtains the tablet finished product in compacting.
Embodiment 2 prepares capsule
Get 10 kilograms of Radix Aconitis, 11 kilograms of Radix Aconiti Kusnezoffii, 8 kilograms of Semen Strychni, 9 kilograms of Herba Asaris, 11 kilograms of Rhizoma Arisaematiss, 12 kilograms of the Rhizoma Pinelliaes, 13 kilograms of Rhizoma Paridis, 12 kilograms of LIAODAOZHU, 8 kilograms of bee venom, 18 kilograms of Scorpios, 6 kilograms of Scolopendras, 10 kilograms, Radix Notoginseng.Each medicine is merged and soaks into rear decoction 3 times, decocted 30～120 minutes at every turn, merge decoction liquor and filter, be condensed into clear paste, dry granulation, incapsulate.
Embodiment 3 prepares oral liquid
Get 10 kilograms of Radix Aconitis, 11 kilograms of Radix Aconiti Kusnezoffii, 8 kilograms of Semen Strychni, 9 kilograms of Herba Asaris, 11 kilograms of Rhizoma Arisaematiss, 12 kilograms of the Rhizoma Pinelliaes, 13 kilograms of Rhizoma Paridis, 12 kilograms of LIAODAOZHU, 8 kilograms of bee venom, 18 kilograms of Scorpios, 6 kilograms of Scolopendras, 10 kilograms, Radix Notoginseng, 20 kilograms of Chinese liquor, be mixed and decoct twice.Add 8 times of amounts of water at every turn, boiled 1 hour.Before decocting for the first time, first soak half an hour.After decocting, collect merging filtrate, by filtrate put into the vacuum concentration pan decompression (43-47 ℃ ,-0.093～0.097Mpa) is concentrated into relative density 1.23～1.27 (25 ℃); Add 95% ethanol to containing alcohol amount 50%～70%, standing 72 hours, filter; Filtrate recycling ethanol is to without alcohol, distinguishing the flavor of; Gained extractum adds purified water and stirs in right amount, boils 30 minutes, is cooled to room temperature, and cold preservation 48 hours filters, and regulates pH value to 7.0, accurately mends purified water to full dose, filters.Canned after reason bottle, with 100 ℃ of flowing steam sterilizations 30 minutes, make oral liquid.
The routine clinical efficacy of the dermopathic Chinese medicine composition 104 of experimental example application Drug therapy rheumatism of the present invention is summed up
The inventor applies the thousands of examples of the dermopathic Chinese medicine composition patient of Drug therapy rheumatism of the present invention in many decades, obtain good result.Now select the 104 routine final reports that term calendar year 2001 to 2008 interocclusal record is complete as follows.
, the median age 51 years old; All cases all are diagnosed as psoriasis according to medical history, skin lesion feature, whole body performance, and similar sick kind the such as seborrheic dermatitis, pityriasis rosea, lichen planus got rid of in Differential Diagnosis.1 of the equal medication of all cases, more than the course for the treatment of, is observed more than 3 months after treatment finishes.After 1 course for the treatment of under medication, drug withdrawal, observe 3 months persons of less than and do not include this group statistics in.This group 104 its Staging of course of disease of example and Clinical typing are listed as follows.
The routine psoriasis course of disease of this group of table 1 104 distributes
| The course of disease (year) | Total case | ～3 | ～5 | ～10 | ～20 | ～30 | More than 30 |
| Example | 104 | 18 | 20 | 32 | 20 | 10 | 4 |
| Ratio (%) | 100 | 17.3 | 19.2 | 30.8 | 19.2 | 9.6 | 3.8 |
The routine psoriasis Clinical typing of this group of table 2 104
(2) Therapeutic Method
This group case gives the tablet prepared by embodiment 1 method, or by traditional method, makes decoct by the present invention's formula.Every day, dosage was equivalent to crude drug 210 grams, and minutes 2～4 times oral.60 days is a course for the treatment of.Observe the variation of skin lesion and General Symptoms, while needing, dosage and adjuvant drug adjustment are entered to next course for the treatment of.Finish treatment maximum 4 courses for the treatment of.For the clinical cure person, gave after treatment 3 months, give and take vitamin B1, B12, C and calcium preparation etc.
(3) therapeutic outcome
Most patients show as the variation of three phases in therapeutic process, each stage is about as much as a course for the treatment of.First stage is dispersed the phase for endogenous toxin under drug effect, and the scope of skin lesion does not only reduce, and can spread to some extent on the contrary; Second stage starts convergence for stable the carrying out the phase after endogenous toxin is dispersed, skin lesion, and gargalesthesia alleviates gradually; Phase III is skin lesion paracmasis, and speckle gradually row disappears, and replaces cutaneous pigmentation, and the skin gargalesthesia disappears fully or substantially disappears.
Curative effect judging standard:
Cure: skin lesion is disappeared fully, and without gargalesthesia, pigmentation is left in part, and follow-up observation is the nothing recurrence more than 3 months;
Produce effects: skin lesion 80% is disappeared, and occasionally slight gargalesthesia is arranged, and starts to occur cutaneous pigmentation;
Improvement: skin lesion speckle quantity dough-making powder is long-pending to be reduced to some extent, but the amount reduced does not reach 50% of the front skin lesion gross area for the treatment of, and the skin gargalesthesia alleviates to some extent;
Invalid: skin lesion area and skin gargalesthesia have no significant change before treating.
By above-mentioned curative effect judging standard, the routine psoriasis application of this group 104 curative effect of medication of the present invention is analyzed as table 3.
The routine psoriasis efficacy analysis of this group of table 3 104
| The curative effect grade | Total case | Cure | Produce effects | Take a turn for the better | Invalid | Effective percentage |
| Example | 104 | 83 | 11 | 5 | 5 | 99 |
| Ratio (%) | 100 | 79.8 | 10.6 | 4.8 | 4.8 | 95.2 |
Table 3 shows, the various psoriatic effective percentage of Drug therapy of the present invention reaches 95.2%, and cure rate reaches 79.8%.Wherein healing person's 83 examples are all three courses for the treatment of of medication.
Claims (5)
1. treat the dermopathic Chinese medicine composition of rheumatism for one kind, it is characterized in that, the pharmacodynamic raw materials of making it comprises the medicine of following weight proportioning: 5～13 parts of Radix Aconitis, 5～12 parts of Radix Aconiti Kusnezoffii, 5～10 parts of Semen Strychni, 5～14 parts of Herba Asaris, 5～15 parts of Rhizoma Arisaematiss, 5～25 parts of the Rhizoma Pinelliaes, 5～17 parts of Rhizoma Paridis, 5～18 parts of LIAODAOZHU, 5～19 parts of bee venom, 5～25 parts of Scorpios, 5～27 parts of Scolopendras.
2. the dermopathic Chinese medicine composition for the treatment of rheumatism according to claim 1, it is characterized in that, the weight proportion of pharmacodynamic raw materials used is, 8 parts of Radix Aconitis, 6 parts of Radix Aconiti Kusnezoffii, 8 parts of Semen Strychni, 12 parts of Herba Asaris, 7 parts of Rhizoma Arisaematiss, 18 parts of the Rhizoma Pinelliaes, 11 parts of Rhizoma Paridis, 10 parts of LIAODAOZHU, 12 parts of bee venom, 13 parts of Scorpios, 14 parts of Scolopendras.
3. the dermopathic Chinese medicine composition for the treatment of rheumatism according to claim 1, is characterized in that, pharmacodynamic raw materials used also comprises Radix Notoginseng 5～30 weight portions.
4. the dermopathic Chinese medicine composition for the treatment of rheumatism according to claim 2, is characterized in that, pharmacodynamic raw materials used also comprises Chinese liquor 30 weight portions.
5. according to the dermopathic Chinese medicine composition of the described treatment rheumatism of the arbitrary claim of claim 1～4, it is characterized in that, the pharmaceutical dosage form that pharmaceutical composition is made is any dosage form in honeyed pill, the watered pill, tablet, capsule, granular pattern electuary, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102608074A CN103405599A (en) | 2013-06-27 | 2013-06-27 | Traditional Chinese medicine composition for treating rheumatic dermatosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102608074A CN103405599A (en) | 2013-06-27 | 2013-06-27 | Traditional Chinese medicine composition for treating rheumatic dermatosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103405599A true CN103405599A (en) | 2013-11-27 |
Family
ID=49598673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102608074A Pending CN103405599A (en) | 2013-06-27 | 2013-06-27 | Traditional Chinese medicine composition for treating rheumatic dermatosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103405599A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110123926A (en) * | 2019-06-20 | 2019-08-16 | 湖北穆兰同大科技有限公司 | A kind of nursing ointment and preparation method thereof |
-
2013
- 2013-06-27 CN CN2013102608074A patent/CN103405599A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110123926A (en) * | 2019-06-20 | 2019-08-16 | 湖北穆兰同大科技有限公司 | A kind of nursing ointment and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102580000B (en) | Medicament for curing cancer pain and preparation method thereof | |
| CN1327875C (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN102698014A (en) | Chinese medicinal composition for treating bone-related diseases and preparation method and application thereof | |
| CN112972635A (en) | A Chinese medicinal composition for treating chronic kidney diseases and chronic renal failure | |
| CN101897933B (en) | Chinese patent medicament for treating leucoderma | |
| CN101647985B (en) | Medicament composition for treating psoriasis | |
| CN102430097A (en) | Chinese medicine for treating vitiligo | |
| CN102727648A (en) | Chinese medicinal composition for treating vitiligo | |
| CN102579816B (en) | Brain-invigorating tablets and preparation method thereof | |
| CN104383421A (en) | Pharmaceutical preparation for treating insomnia and dreaminess | |
| CN104383420A (en) | Preparation method of pharmaceutical preparation for treating insomnia and dreaminess | |
| CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN106344888B (en) | Chinese medicine composition and its preparation method and application with strengthening the spleen and replenishing qi function | |
| CN103405599A (en) | Traditional Chinese medicine composition for treating rheumatic dermatosis | |
| CN104189289B (en) | A kind of Chinese medicine for the treatment of acute icterohepatitis and preparation method thereof | |
| CN103550744B (en) | A kind of pure Chinese medicinal preparation for oral ulcer | |
| CN107137504B (en) | Health food for improving sleep and enhancing immunity | |
| CN112043773A (en) | Intelligent system preparation for conditioning physique and preventing and treating various psoriasis and preparation method thereof | |
| CN104043008A (en) | External traditional Chinese medicinal composition for treating myofascitis and preparation method thereof | |
| CN103536879A (en) | Pharmaceutical composition for treating diabetes mellitus and preparation method thereof | |
| CN104740579B (en) | Premenstrual peace piece and its preparation technology | |
| CN116688058B (en) | Li medicine for impotence, preparation method and application thereof | |
| CN102727730B (en) | Traditional Chinese medicinal compound preparation for treating male infertility and its preparation method | |
| CN106540044A (en) | It is a kind of to treat pharmaceutical composition of rheumatoid arthritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131127 |